Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWIN II)

A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis

Existing samples:

  • Malignant tumor of lung (disorder)

Bespoke collection capabilities:

  • Malignant tumor of lung (disorder)

Contact Information

Email:
ctc.darwin2@ucl.ac.uk
Address:

CRUK & UCL Cancer Trials Centre
90 Tottenham Court Road
London
Greater London
W1T 4TJ
England

Last Updated: 19/10/2018


Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A
2020 N/A N/A N/A N/A N/A N/A
2021 N/A N/A N/A N/A N/A N/A
2022 N/A N/A N/A N/A N/A N/A